company background image
ALNY

Alnylam Pharmaceuticals NasdaqGS:ALNY Stock Report

Last Price

US$225.40

Market Cap

US$27.7b

7D

-1.2%

1Y

55.5%

Updated

31 Jan, 2023

Data

Company Financials +

Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Stock Report

Mkt Cap: US$27.7b

ALNY Stock Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

ALNY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

New

Notes are coming soon

Alnylam Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$225.40
52 Week HighUS$242.97
52 Week LowUS$117.58
Beta0.50
1 Month Change-5.15%
3 Month Change5.16%
1 Year Change55.52%
3 Year Change87.90%
5 Year Change84.50%
Change since IPO3,650.42%

Recent News & Updates

Recent updates

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Jun 21
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 20
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Jul 03
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 48%?

Jun 07
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 48%?

We Discuss Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO May Deserve A Higher Pay Packet

May 12
We Discuss Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO May Deserve A Higher Pay Packet

Shareholder Returns

ALNYUS BiotechsUS Market
7D-1.2%-1.4%0.2%
1Y55.5%1.2%-13.6%

Return vs Industry: ALNY exceeded the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ALNY exceeded the US Market which returned -9.2% over the past year.

Price Volatility

Is ALNY's price volatile compared to industry and market?
ALNY volatility
ALNY Average Weekly Movement5.8%
Biotechs Industry Average Movement12.3%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: ALNY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ALNY's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20021,665Yvonne Greenstreethttps://www.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
ALNY fundamental statistics
Market CapUS$27.73b
Earnings (TTM)-US$1.18b
Revenue (TTM)US$960.92m

28.9x

P/S Ratio

-23.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALNY income statement (TTM)
RevenueUS$960.92m
Cost of RevenueUS$155.22m
Gross ProfitUS$805.70m
Other ExpensesUS$1.99b
Earnings-US$1.18b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-9.61
Gross Margin83.85%
Net Profit Margin-123.02%
Debt/Equity Ratio-1,502.1%

How did ALNY perform over the long term?

See historical performance and comparison